GlassScriptPhysician profile
Christine Baidwan
NPI 1487814562
$6,978.32
in general payments reported to CMS, 2019-2025
47 companies · $1,524 in 2025
The $1,524 reported for 2025 was more than what 93% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $572 · 2020: $400 · 2021: $1,050 · 2022: $553 · 2023: $2,338 · 2024: $542 · 2025: $1,524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,625 · Travel and Lodging: $1,591 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,000 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,624.64 |
| Travel and Lodging | $1,590.79 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,000.00 |
| Education | $187.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,743.94 | 2023-2025 | Da Vinci Surgical System |
| Abbvie INC. | $791.14 | 2019-2024 | Lo Loestrin Fe |
| Astellas Pharma US INC | $382.19 | 2023-2025 | Veozah |
| Organon LLC | $343.88 | 2021-2025 | Nexplanon |
| Pfizer INC. | $256.10 | 2019-2025 | |
| Exeltis, USA INC. | $216.37 | 2021-2025 | Slynd |
| Hologic Sales and Service, LLC | $201.45 | 2019-2025 | Aptima, Thinprep 2000 Processor, Novasure |
| Bayer Healthcare Pharmaceuticals INC. | $166.55 | 2019-2024 | |
| Daiichi Sankyo INC. | $138.33 | 2019-2022 | |
| Duchesnay USA Incorporated | $129.13 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $122.71 | 2021 | |
| Coopersurgical, INC. | $119.16 | 2020 | |
| Sage Therapeutics, LLC | $117.35 | 2024-2025 | Zurzuvae |
| Gynesonics, INC. | $97.45 | 2021 | |
| Millicent US INC | $83.78 | 2020-2024 | Intrarosa |
Show all 46 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Baidwan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.